The COVID-19 vaccine, developed by Pfizer () and BioNTech (), is effective in the prevention of both symptomatic and severe disease in people with chronic diseases such as diabetes and heart disease.
An analysis of nearly 1.4 million people by Israel̵7;s largest healthcare provider will provide further hope for countries when they are armed with citizens, especially those at risk and control. The outbreak of the epidemic has killed more than 3.1 million people.
The vaccine was 80% effective in preventing symptomatic infections for people with chronic heart or kidney disease, 86% for type 2 diabetes patients, 75% for cerebrovascular disease, and 84% for people with immunodeficiency. Clalit Research Institue study
For people who are vaccinated and have three or more chronic conditions or risk factors, such as heart disease, neurological disease, chronic kidney disease, cystic fibrosis, smoking, pregnancy, or obesity, research shows. 88% effectiveness in preventing symptomatic infections.
It is more than 90% effective in preventing severe disease for people with type 2 diabetes, cardiovascular disease, and 100% for people with immunodeficiency.
The data is the latest from Israel that a universal and digital healthcare system and rapid vaccination program give researchers insights into the potential of the Clalit vaccine covering more than half of Israel’s population.
The study results were 96% lower than the overall vaccine efficacy seven days or more after the second dose, which was found in the 95% of studies and efficacy found in clinical trials last year.
But the researchers said they were optimistic that the vaccine still provides protection against serious illness in people who become infected after being given the shot.
“Prevention is slightly reduced in patients with multiple co-existing diseases. These results are very encouraging, as they suggest that most COVID-19 patients are protected by vaccination, even in the elderly and the elderly. Chronically ill, ”said Ran Balicer, chief innovation officer at Clalit.
“People with a wide range of chronic or severe chronic illnesses should be vaccinated because vaccines are very effective in preventing the complications that are expected to be high,” Balicer said.
The research was also conducted by Harvard and the University of Michigan and published Thursday in the New England Journal of Medicine.
The Clalit study compared approximately 700,000 people who were vaccinated between Dec. 20, 2020, and Feb. 14, with a cohort of people who didn’t receive the same dose, matched age, gender, and other traits.
A subgroup of people with the chronic disease is approximately 130,000, Balicer said.
More than half of Israel’s 9.3 million people have been fully vaccinated since the vaccination push began in late December. COVID-19 cases have continued to decline since mid-January due to the economy. Most of them are open. Read more about studying in Malaysia
Until mid-April, Israel had reported 98 percent fewer coronavirus cases, 93 percent fewer serious illnesses, and 87 percent fewer deaths from COVID-19, according to Eran Segal, a data scientist at the Weizmann Institute of Science.
Baliser said that although Israel is not yet level “Herd immunity”, but the rapid decline is “This is testament to the potential of many vaccinations to take us out of harm’s way.
Confidence, excitement and breadth
The larger sample size allowed researchers to look at a more subset of people with specific chronic diseases that did not need to be investigated in vaccine clinical trials.
It was also found that the vaccine was 92% effective in preventing COVID-19 in people older than 70, 96% for overweight and 93% for obese, and providing 90% of coverage for people. With high blood pressure
Danny Altmann, professor of immunology at Imperial College London, said the study is one of the first real-world studies to present such detailed information in a vaccinated subgroup.
“Moving to production, the performance still looks great. But there are inevitably poor responses to vaccines, ”he said in an email to Reuters.
“We need to know who they are, why and what they can do to continue helping our immunity. We need to look at the results of each large-scale study for different patient groups.”
Rochelle Walensky, director of the U.S. Centers for Disease Control and Prevention (CDC), said of the 84 million fully vaccinated people in the United States, fewer than 6,000 became ill with COVID-19 more than two weeks after receiving the drug. fully
Of those, nearly 400 were hospitalized, and about 75 died, according to the CDC.The hospitalizations and some deaths were not caused by COVID-19 infection.
Pfizer’s late-stage clinical trials included people with common medical conditions. The most frequently reported congenital diseases were obesity (35.1%), diabetes (8.4% with and without chronic complications) and lung disease (7.8%), a spokesperson said.
Our Standard: The Thomson Reuters Trust Principle.